Cargando…

Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran

INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is one of the scariest chemotherapy-induced adverse effects. We evaluated the adherence to the 2017 American Society of Clinical Oncology (ASCO), the latest guideline recommendations, for the management of acute CINV at our institute. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebrahimi, Mahbobeh, Mehrzad, Valiollah, Moghaddas, Azadeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568894/
https://www.ncbi.nlm.nih.gov/pubmed/32592350
http://dx.doi.org/10.31557/APJCP.2020.21.6.1567
_version_ 1783596616099299328
author Ebrahimi, Mahbobeh
Mehrzad, Valiollah
Moghaddas, Azadeh
author_facet Ebrahimi, Mahbobeh
Mehrzad, Valiollah
Moghaddas, Azadeh
author_sort Ebrahimi, Mahbobeh
collection PubMed
description INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is one of the scariest chemotherapy-induced adverse effects. We evaluated the adherence to the 2017 American Society of Clinical Oncology (ASCO), the latest guideline recommendations, for the management of acute CINV at our institute. METHODS: During a 6-months cross-sectional study on outpatient’s cancer patients, we collected data from the prescription documents during temporary hospitalization and compared the results with ASCO guideline recommendations. RESULTS: The most prescribed prophylactic regimens for the management of CINV were combination of aprepitant, granisetron, and dexamethasone and metoclopramide (51.8%). Regarding prescription compatibility in our center with ASCO guideline recommnedations, selection of different regimens for prophylaxis of acute CINV in our institute was compliant in 0 %, 22%, 4%, and 40% of high, moderate, low, and minimal emetogenic potential of chemotherapy regimen groupss, respectively. CONCLUSION: Although our hospital is a referral and university-affiliated center, adherence to the ASCO guideline recommendations for prophylaxis of CINV was poor.
format Online
Article
Text
id pubmed-7568894
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-75688942020-10-30 Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran Ebrahimi, Mahbobeh Mehrzad, Valiollah Moghaddas, Azadeh Asian Pac J Cancer Prev Research Article INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is one of the scariest chemotherapy-induced adverse effects. We evaluated the adherence to the 2017 American Society of Clinical Oncology (ASCO), the latest guideline recommendations, for the management of acute CINV at our institute. METHODS: During a 6-months cross-sectional study on outpatient’s cancer patients, we collected data from the prescription documents during temporary hospitalization and compared the results with ASCO guideline recommendations. RESULTS: The most prescribed prophylactic regimens for the management of CINV were combination of aprepitant, granisetron, and dexamethasone and metoclopramide (51.8%). Regarding prescription compatibility in our center with ASCO guideline recommnedations, selection of different regimens for prophylaxis of acute CINV in our institute was compliant in 0 %, 22%, 4%, and 40% of high, moderate, low, and minimal emetogenic potential of chemotherapy regimen groupss, respectively. CONCLUSION: Although our hospital is a referral and university-affiliated center, adherence to the ASCO guideline recommendations for prophylaxis of CINV was poor. West Asia Organization for Cancer Prevention 2020-06 /pmc/articles/PMC7568894/ /pubmed/32592350 http://dx.doi.org/10.31557/APJCP.2020.21.6.1567 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ebrahimi, Mahbobeh
Mehrzad, Valiollah
Moghaddas, Azadeh
Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran
title Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran
title_full Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran
title_fullStr Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran
title_full_unstemmed Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran
title_short Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran
title_sort adherence to asco for prophylaxis of acute chemotherapy-induced nausea and vomiting in iran
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568894/
https://www.ncbi.nlm.nih.gov/pubmed/32592350
http://dx.doi.org/10.31557/APJCP.2020.21.6.1567
work_keys_str_mv AT ebrahimimahbobeh adherencetoascoforprophylaxisofacutechemotherapyinducednauseaandvomitinginiran
AT mehrzadvaliollah adherencetoascoforprophylaxisofacutechemotherapyinducednauseaandvomitinginiran
AT moghaddasazadeh adherencetoascoforprophylaxisofacutechemotherapyinducednauseaandvomitinginiran